Obsessive compulsive disorder and the glutamatergic system

Current Opinion in Psychiatry

Volumn 27, Issue 1, 2014, Pages 32-37

  Kariuki Nyuthe, Catherine ^a   Gomez Mancilla, Baltazar ^b   Stein, Dan J ^c  

^a MAROONDAH HOSPITAL   (Australia)

^b NOVARTIS PHARMA AG   (Switzerland)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

clinical trials; genetics; glutamate; obsessive compulsive disorder

Indexed keywords

ACETYLCYSTEINE; AMANTADINE; CLOMIPRAMINE; CYCLOSERINE; FLUOXETINE; GLUTAMATE RECEPTOR AGONIST; GLUTAMIC ACID; KETAMINE; LAMOTRIGINE; MEMANTINE; RILUZOLE; SEROTONIN UPTAKE INHIBITOR; TOPIRAMATE;

BRAIN REGION; CENTRAL NERVOUS SYSTEM; CLINICAL RESEARCH; COGNITIVE THERAPY; DLGAP3 GENE; DOPAMINERGIC SYSTEM; DRUG EFFICACY; DRUG TOLERABILITY; EVIDENCE BASED PRACTICE; GENE; GENE DELETION; GENETIC SUSCEPTIBILITY; GLUTAMATERGIC SYSTEM; HUMAN; NEUROBIOLOGY; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OBSESSIVE COMPULSIVE DISORDER; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SLITRK5 GENE; SYMPTOMATOLOGY; TRICHOTILLOMANIA;

ANIMALS; ANTICONVULSANTS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; EXCITATORY AMINO ACID AGENTS; HUMANS; NEUROIMAGING; OBSESSIVE-COMPULSIVE DISORDER; SEROTONIN UPTAKE INHIBITORS;

EID: 84889887818     PISSN: 09517367     EISSN: 14736578     Source Type: Journal    
DOI: 10.1097/YCO.0000000000000017     Document Type: Review

References (75)

1. Murray CJL, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020. Global Burden of Disease Study. Lancet 1997; 349:1498-1504
2. Karno M, Golding JM, Sorenson SB, et al. The epidemiology of obsessivecompulsive disorder in five US communities. Arch Gen Psychiatry 1988; 45:1094-1099
3. Heyman I. Obsessive-compulsive disorder. Clinical review. BMJ 2006; 333:424
4. Newth S, Rachman S. The concealment of obsession. Behav Res Ther 2001; 39:457-464
5. Ruscio AM, Stein DJ, Chiu WT, et al. The epidemiology of obsessivecompulsive disorder in the National Comorbidity Survey Replication. Mol Psychiatry 2010; 15:53-63
6. Mataix-Cols D, Wooderson S, Lawrence N, et al. Distinct neural correlates of washing, checking and hoarding symptom dimensions in obsessive-compulsive disorder. Arch Gen Psychiatry 2004; 61:564-576
7. Leckman JF, Bloch MH, King RA. Symptom dimensions and subtypes of obsessive-compulsive disorder: A developmental perspective. Dialogues Clin Neurosci 2009; 11:21-33
8. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed. Arlington, VA: American Psychiatric Publishing; 2013
9. Stein DJ, Fineberg NA, Bienvenu OJ, et al. Should OCD be classified as an anxiety disorder in DSM-V? Depress Anxiety 2010; 27:495-506
10. Phillips KA, Stein DJ, Rauch SL, et al. Should an obsessive-compulsive spectrum grouping of disorders be included in DSM-V? Depress Anxiety 2010; 27:528-555
11. Ahmari SE, Spellman T, Douglass NL, et al. Repeated cortico-striatal stimulation generates persistent OCD-like behavior. Science 2013; 340:1234- 1239
12. Zemelman BV, Lee GA, Ng M, et al. Selective photostimulation of genetically charged neurons. Neuron 2002; 33:15-22
13. Burguiere E, Monteiro P, Feng G, et al. Optogenetic stimulation of the lateral orbitofronto-striatal pathway suppresses compulsive behaviors. Science 2013; 340:1243-1246
14. McGrath MJ, Campbell KM, Parks CR, et al. Glutamatergic drugs exacerbate symptomatic behavior in a transgenic model of comorbid Tourette's syndrome and obsessive-compulsive disorder. Brain Res 2000; 877:23-30
15. Wu K, Hanna GL, Rosenberg DR, et al. The role of glutamate signaling in the pathogenesis and treatment of obsessive-compulsive disorder. Pharmacol Biochem Behav 2012; 100:726-735
16. Ting JT, FengG. Neurobiology of obsessive-compulsive disorder: Insights into neural circuitry dysfunction through mouse genetics. Curr Opin Neurobiol 2010; 21:842-848
17. Boardman L, van der Merwe L, Lochner C, et al. Investigating SAPAP3 variants in the etiology of obsessive-compulsive disorder and trichotillomania in the South African white population. Compr Psychiatry 2011; 52:181- 187
18. Crane J, Fagerness J, Osiecki L, et al. Family-based genetic association study of DLGAP3 in Tourette syndrome. Am J Med Genet B Neuropsychiatr Genet 2011; 156B:108-114
19. Shmelkov SV, Hormigo A, Jing D, et al. Slitrk5 deficiency impairs corticostriatal circuitry and leads to obsessive-compulsive-like behaviors in mice. Nat Med 2010; 16:598-602
20. Rosenberg DR, Keshavan MS. AE Bennett Research Award. Toward a neurodevelopmental model of obsessive-compulsive disorder. Biol Psychiatry 1998; 43:623-640
21. Albelda N, Bar-On N, Joel D. The role of NMDA receptors in the signal attenuation rat model of obsessive-compulsive disorder. Psychopharmacology (Berl) 2010; 210:13-24
22. Egashira N, Okuno R, Harada S, et al. Effects of glutamate-related drugs on marble-burying behavior in mice: Implications for obsessive-compulsive disorder. Eur J Pharmacol 2008; 586:164-170
23. Abramowitz JS, Taylor S, McKay D, et al. Animal models of obsessivecompulsive disorder. Biol Psychiatry 2011; 69:e29-e30
24. Chamberlain SR, Menzies L, Hampshire A, et al. Orbitofrontal dysfunction in patients with obsessive-compulsive disorder and their unaffected relatives. Science 2008; 321:421-422
25. Lochner C, Seedat S, Du Toit PL, et al. Obsessive-compulsive disorder and trichotillomania: A phenomenological comparison. BMC Psychiatry 2005; 5:1-10
26. Baxter LR, Phelps ME, Mazziotta JC, et al. Local cerebral glucose metabolic rates in obsessive-compulsive disorder. A comparison with rates in unipolar depression and in normal controls. Arch Gen Psychiatry 1987; 44:211-218
27. Bergqvist PB, Bouchard C, Blier P, et al. Effect of long-term administration of antidepressant treatment on serotonin release in brain regions involved in obsessive-compulsive disorder. Biol Psychiatry 1999; 45:164-174
28. Menzies L, Chamberlain SR, Laird AR, et al. Integrating evidence from neuroimaging and neuropsychological studies of obsessive-compulsive disorder: The orbitofronto-striatal model revisited. Neurosci Biobehav Rev 2008; 32:525-529
29. Whiteside SP, Port JD, Abramowitz JS. A meta-analysis of functional imaging in obsessive-compulsive disorder. Psychiatry Res Neuroimaging 2004; 132:69-79
30. Wu K, Hanna GL, Easter P, et al. Glutamate system genes and brain volume alterations in pediatric obsessive-compulsive disorder: A preliminary study. Psychiatry Res 2013; 211:214-220
31. Radua J, Mataix-Cols D. Voxel-wise meta-analysis of grey matter changes in obsessive-compulsive disorder. Br J Psychiatry 2009; 195:393-402
32. Saxena S, Brody AL, Ho ML, et al. Cerebral metabolism in major depression and obsessive-compulsive disorder occurring separately and concurrently. Biol Psychiatry 2001; 50:159-170; b.
33. Arnold PD, Macmaster FP, Richter MA, et al. Glutamate receptor gene (GRIN2B) associated with reduced anterior cingulate glutamatergic concentration in pediatric obsessive-compulsive disorder. Psychiatry Res 2009; 172:136-139
34. Busatto GF, Zamignani DR, Buchpiguel CA, et al. A voxel-based investigation of regional cerebral blood flow abnormalities in obsessive-compulsive disorder using single-photo emission tomography (SPECT). Psychiatry Res 2000; 99:15-27
35. Cottraux J, Gerard D, Cinotti L, et al. A controlled positron emission tomography (PET) study of obsessive and neutral auditory stimulation in obsessivecompulsive disorder with checking rituals. Psychiatry Res 1996; 60:101- 112
36. Ting JT, Feng G. Glutamatergic synaptic dysfunction and obsessive-compulsive disorder. Curr Chem Genomics 2008; 2:62-75
37. Rosenberg DR, MacMaster FP, Keshavan MS, et al. Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine. J Am Acad Child Adolesc Psychiatry 2000; 39:1096-1103
38. Pittenger C, Bloch MH, Williams K. Glutamate abnormalities in obsessivecompulsive disorder: Neurobiology, pathophysiology and treatment. Pharmacol Therap 2011; 132:314-332
39. Brennan BP, Rauch SL, Jensen JE, et al. A critical review of magnetic resonance spectroscopy studies in obsessive-compulsive disorder. Biol Psychiatry 2013; 73:24-31
40. Chakrabarty K, Bhattacharyya S, Christopher R, et al. Glutamatergic dysfunction in OCD. Neuropsychopharmacology 2005; 30:1735-1740
41. Bhattacharyya S, Khanna S, Chakrabarty K, et al. Antibrain autoantibodies and altered excitatory neurotransmitters in obsessive-compulsive disorder. Neuropsychopharmacology 2009; 34:2489-2496
42. Wang Y, Adamczyk A, Shugart Y, et al. A screen of SLC1A1 for OCD-related alleles. Am J Med Genet B Neuropsychiatr Genet 2010; 153B:675-679
43. Samuels J, Wang Y, Riddle M, et al. Comprehensive family-based association study of the glutamate transporter gene SLC1A1 in obsessive-compulsive disorder. Am J Med Genet B Neuropsychiatr Genet 2011; 156:472-477
44. Arnold PD, Sicard T, Burroughs E, et al. Glutamate transporter gene SLC1A1 associated with obsessive-compulsive disorder. Arch Gen Psychiatry 2006; 63:769-776
45. Dickel DE, Veenstra-VanderWeele J, Cox NJ, et al. Association testing of the positional and functional candidate gene SLC1A1/EAAC1 in early-onset obsessive-compulsive disorder. Arch Gen Psychiatry 2006; 63:778-785
46. Stewart SE, Fagerness JA, Platko J, et al. Association of the SLC1A1 glutamate transporter gene and obsessive-compulsive disorder. Am J Med Genet B Neuropsychiar Genet 2007; 144B:1027-1033
47. Delorme R, Krebs MO, Chabane N, et al. Frequency and transmission of glutamate receptors GRIK2 and GRIK3 polymorphisms in patients with obsessive-compulsive disorder. Neuroreport 2004; 15:699-702
48. Stewart SE, Fagerness J, Moorjani P, et al. Family-based association between obsessive-compulsive disorder and glutamate receptor candidate genes. WCPG; 2008. Annual Meeting
49. Hemmings SM, Stein DJ. The current status of association studies in obsessive-compulsive disorder. Psychiatr Clin North Am 2006; 29:411-444
50. Stewart SE, Yu D, Scharf JM, et al. Genome-wide association study of obsessive-compulsive disorder. Mol Psychiatry 2013; 18:788-798
51. Vythilingum B, Cartwright C, Hollander E. Pharmacotherapy of obsessivecompulsive disorder: Experience with the selective serotonin reuptake inhibitors. Int Clin Psychopharmacol 2000; 15 ((suppl)):7-13
52. Abramowitz JS, Jacoby RJ. Obsessive compulsive disorder. Anxiety disorders: A guide for integrating psychopharmacology and psychotherapy. In: Stahl SM, Moore BA, editors. London: Routledge Publishers; 2013; vol. 6. pp. 134-154
53. Ipser JC, Carey P, Dhansay Y, et al. Pharmacotherapy augmentation strategies for treatment-resistant anxiety disorders. Cochrane Database Syst Rev 2006; Art.no: CD0005473
54. Arumugham SS, Reddy JYC. Augmentation strategies in obsessive-compulsive disorder. Expert Rev Neurother 2013; 13:187-203
55. Coric V, Taskiran S, Pittenger C, et al. Riluzole augmentation in treatmentresistant obsessive-compulsive disorder: An open-label trial. Biol Psychiatry 2005; 58:424-428
56. Grant P, Lougee L, Hirschtritt M. An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder. J Child Adolesc Psychopharmacol 2007; 17:761-767
57. Aboujaoude E, Barry JJ, Gamel N. Memantine augmentation in treatmentresistant obsessive-compulsive disorder: An open-label trial. J Clin Psychopharmacol 2009; 29:51-55
58. Feusner JD, Kerwin L, Saxena S, et al. Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: An open-label trial. Psychopharmacol Bull 2009; 42:81-93
59. Bloch MH, Wasylink S, Landeros-Weisenberger A, et al. Effects of ketamine in treatment-refractory obsessive-compulsive disorder. Biol Psychiatry 2012; 72:964-970
60. Rodriguez CI, Kegeles LS, Levinson A, et al. Randomized controlled crossover trial of ketamine in obsessive-controlled disorder: Proof-of-concept. Neuropsychopharmacology 2013. doi:10.1038/npp.2013.150
61. Arumugham SS, Reddy JYC. Augmentation strategies in obsessive-compulsive disorder: Glutamatergic drugs. Expert Rev Neurother 2013; 13:1-17
62. Mowla A, Khajeian AM, Sahraian A, et al. Topiramate augmentation in resistant OCD: A double-blind placebo-controlled clinical trial. CNS Spectr 2010
63. Bruno A, Mico U, Pandolfo G, et al. Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: A double-blind, placebo-controlled study. J Psychopharmacol 2012; 26:1456- 1462
64. Van Ameringen M, Mancini C, Patterson B, et al. Topiramate augmentation in treatment-resistant obsessive-compulsive disorder: A retrospective, openlabel case series. Depress Anxiety 2006; 23:1-5
65. Berlin HA, Koran LM, Jenike MA, et al. Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 2011; 72:716-721
66. Uzun O. Lamotrigine as an augmentation agent in treatment-resistant obsessive- compulsive disorder: A case report. J Psychopharmacol 2010; 24: 425-427
67. Kumar TC, Khanna S. Lamotrigine augmentation of serotonin re-uptake inhibitors in obsessive-compulsive disorder. Aust N Z J Psychiatry 2000; 34:527-528
68. Lafleur DL, Pittenger C, Kelmendi B, et al. N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder. Psychopharmacology (Berl) 2006; 184:254-256
69. Van Ameringen M, Patterson B, Simpson W, et al. N-acetylcysteine augmentation in treatment resistant obsessive compulsive disorder: A case series. J Obsessive Compulsive Relat Disord 2013; 2:48-52
70. Grant JE, Odlaug BL, Kim SW. N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: A double-blind, placebo-controlled study. Arch Gen Psychiatry 2009; 66:756-763
71. Dean O, Giorlando F, Berk M. N-acetylcysteine in psychiatry: Current therapeutic evidence and potential mechanisms of action. J Psychiatry Neurosci 2011; 36:78-86
72. Bloch MH, Panza KE, Grant JE, et al. N-acetylcysteine in the treatment of pediatric trichotillomania: A randomized, double-blind, placebo-controlled add-on trial. JAACAP 2013; 52:231-240
73. Kushner MG, Kim SW, Donahue C, et al. D-cycloserine augmented exposure therapy for obsessive-compulsive disorder. Biol Psychiatry 2007; 62:835- 838
74. Wilheim S, Buhlmann U, Tolin DF, et al. Augmentation of behavioral therapy with D-cycloserine for obsessive-compulsive disorder. Am J Psychiatry 2008; 165:335-341; quiz 409
75. Storch EA, Merlo LJ, Bengtson M, et al. D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder. Int Clin Psychopharmacol 2007; 22:230-237